172 related articles for article (PubMed ID: 20177795)
1. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
Klinger M; Tamandl D; Eipeldauer S; Hacker S; Herberger B; Kaczirek K; Dorfmeister M; Gruenberger B; Gruenberger T
Ann Surg Oncol; 2010 Aug; 17(8):2059-65. PubMed ID: 20177795
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
[TBL] [Abstract][Full Text] [Related]
3. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.
Vaidyanathan G; Groman A; Wilding G; Fakih MG
Oncology; 2010; 79(1-2):67-71. PubMed ID: 21071992
[TBL] [Abstract][Full Text] [Related]
4. Current role of bevacizumab in colorectal cancer.
Saltz L
Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071
[No Abstract] [Full Text] [Related]
5. Liver resection after FOLFOX with bevacizumab.
Mickle M; Mulcahy MF
Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):12-4. PubMed ID: 17491587
[No Abstract] [Full Text] [Related]
6. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
Seki H; Ozaki T; Shiina M
Cardiovasc Intervent Radiol; 2009 Jul; 32(4):679-86. PubMed ID: 19296157
[TBL] [Abstract][Full Text] [Related]
7. 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study.
Bir A; Tan W; Wilding GE; Lombardo J; Fakih MG
Oncology; 2007; 72(1-2):4-9. PubMed ID: 17971679
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases.
Ribero D; Wang H; Donadon M; Zorzi D; Thomas MB; Eng C; Chang DZ; Curley SA; Abdalla EK; Ellis LM; Vauthey JN
Cancer; 2007 Dec; 110(12):2761-7. PubMed ID: 17960603
[TBL] [Abstract][Full Text] [Related]
9. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
Malik Z; Eng C
Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
[No Abstract] [Full Text] [Related]
10. [A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].
Otsuka S; Inagaki M; Nishie M; Hamano R; Tokunaga N; Takahashi K; Tsunemitsu Y; Miyoshi K; Iwakawa K; Takahashi M; Iwagak H
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2166-8. PubMed ID: 20037358
[TBL] [Abstract][Full Text] [Related]
11. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
[TBL] [Abstract][Full Text] [Related]
12. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.
Aussilhou B; Dokmak S; Faivre S; Paradis V; Vilgrain V; Belghiti J
Ann Surg Oncol; 2009 Jun; 16(6):1553-9. PubMed ID: 19363584
[TBL] [Abstract][Full Text] [Related]
13. Perforating dermatosis in a patient receiving bevacizumab.
Vano-Galvan S; Moreno C; Medina J; Pérez-García B; García-López JL; Jaén P
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):972-4. PubMed ID: 19470057
[No Abstract] [Full Text] [Related]
14. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience.
Siperstein AE; Berber E; Ballem N; Parikh RT
Ann Surg; 2007 Oct; 246(4):559-65; discussion 565-7. PubMed ID: 17893492
[TBL] [Abstract][Full Text] [Related]
15. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Dohn LH; Jensen BV; Larsen FO
Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
[No Abstract] [Full Text] [Related]
16. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
17. Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study).
Beppu T; Emi Y; Tokunaga S; Oki E; Shirabe K; Ueno S; Kuramoto M; Kabashima A; Takahashi I; Samura H; Eguchi S; Akagi Y; Natsugoe S; Ogata Y; Kakeji Y; Baba H; Maehara Y;
Anticancer Res; 2014 Nov; 34(11):6655-62. PubMed ID: 25368271
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
Hurwitz H; Kabbinavar F
Oncology; 2005; 69 Suppl 3():17-24. PubMed ID: 16301832
[TBL] [Abstract][Full Text] [Related]
19. Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases.
Neumann UP; Thelen A; Röcken C; Seehofer D; Bahra M; Riess H; Jonas S; Schmeding M; Pratschke J; Bova R; Neuhaus P
Surgery; 2009 Jul; 146(1):52-9. PubMed ID: 19541010
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
